⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Aegros and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Aegros
↗Macquarie Park, Australia
Aegros is an Australian clinical-stage biopharmaceutical and engineering company that specializes in plasma fractionation technology. Its proprietary HaemaFrac® process is designed to fractionate human plasma into specialty medicinal proteins, such as immunoglobulins, albumin, and clotting factors, with higher yields, lower costs, and greater purity than traditional Cohn/chromatography methods.
The company operates as both a developer of therapeutic plasma drugs and a technology partner for global health systems. Aegros is currently focused on commercializing its hyperimmune products, including a COVID-19 hyperimmune therapy, and building plasma fractionation infrastructure to help nations achieve self-sufficiency in plasma-derived medicinal products (PDMPs).
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$1M-$5M
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Late Stage
Total Raised:$52M
Investors:Fresh Start Australia, L39 Capital, Ray Nolan (Investment Syndicate)
PIPELINE
Stage:Clinical
Lead Drug Stage:Phase 2/3 (COVID-19 Hyperimmune)
Modalities:Plasma-derived therapeutics
Active Trials:1
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Royal Group Plasma Fractionation (Joint Venture)
COMPETITION
Position:Emerging
Competitors:CSL, ExThera Medical, Lindis Blood Care, Hemotune
LEADERSHIP
Key Executives:
Damian Thornton - CEO
Ray Nolan - Chairman
Scientific Founders:Hari Nair, John Manusu
Board Members:Ray Nolan, Anne Duggan, David Burns, John Clarke, Max Grundeman
LINKS
Website:aegros.com.au
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Aegros. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.